PRAP study - Partial versus Radical Adrenalectomy in hereditary Pheochromocytomas.

adrenalectomy cortical-sparing genetics pheochromocytoma total

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 29 05 2024
revised: 15 07 2024
accepted: 20 08 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: aheadofprint

Résumé

Hereditary pheochromocytoma (hPCC) commonly develops bilaterally, causing adrenal insufficiency when standard treatment, radical adrenalectomy (RA), is performed. Partial adrenalectomy (PA) aims to preserve adrenal function, but with higher recurrence rates. This study compares outcomes of PA versus RA in hPCC. Patients with hPCC due to pathogenic variants in RET, VHL, NF1, MAX, and TMEM127 from 12 European centers (1974-2023) were studied retrospectively. Stratified analysis based on surgery type and initial presentation was conducted. Main outcomes included recurrence, adrenal insufficiency, metastasis, and mortality. The study included 256 patients (223 RA, 33 PA). Ipsilateral recurrence rates were 9/223 (4%) after RA versus 5/33 (15%) after PA (P=0.02). Metastasis and mortality did not differ between groups. Overall, 103 patients (40%) underwent bilateral adrenalectomy either synchronously or metachronously (75 RA, 28 PA). Of these, 46% developed adrenal insufficiency after PA.In total, 191 patients presented with initial unilateral disease, of whom 50 (26%) developed metachronous contralateral disease, most commonly in RET, VHL, and MAX. In patients with metachronous bilateral disease, adrenal insufficiency developed in 3/4 (75%) when PA was performed as first operation followed by RA, compared to 1/7 (14%) when PA was performed as second operation after prior RA (P=0.09). In patients with hPCC undergoing PA, local recurrence rates are higher than after RA, but metastasis and disease-specific mortality are similar. Therefore, PA seems a safe method to preserve adrenal function in patients with hPCC, both in cases of synchronous and metachronous bilateral disease, when performed as second operation.

Identifiants

pubmed: 39171965
pii: 7738838
doi: 10.1093/ejendo/lvae108
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.

Auteurs

Kai Xu (K)

Radboud University Medical Center, Department of Internal Medicine, Division of Endocrinology, Nijmegen, the Netherlands.

Johan F Langenhuijsen (JF)

Radboud University Medical Center, Department of Urology, Nijmegen, the Netherlands.

Charlotte L Viëtor (CL)

Erasmus MC Cancer Institute, Department of Surgical Oncology and Gastrointestinal Surgery, Rotterdam, the Netherlands.

Richard A Feelders (RA)

Erasmus MC, Department of Internal Medicine, Division of Endocrinology, Rotterdam, the Netherlands.

Tessa M van Ginhoven (TM)

Erasmus MC Cancer Institute, Department of Surgical Oncology and Gastrointestinal Surgery, Rotterdam, the Netherlands.

Yasir S Elhassan (YS)

University of Birmingham, Institute of Metabolism and Systems Research, Birmingham, United Kingdom.
Birmingham Health Partners, Centre for Endocrinology, Diabetes and Metabolism, Birmingham, United Kingdom.

Fabio Bioletto (F)

University of Turin, Department of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, Turin, Italy.

Mirko Parasiliti-Caprino (M)

University of Turin, Department of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, Turin, Italy.

Wouter T Zandee (WT)

University Medical Center Groningen, Department of Internal Medicine, Division of Endocrinology, Groningen, the Netherlands.

Schelto Kruijff (S)

University Medical Center Groningen, Department of Surgery, Groningen, the Netherlands.

Samuel Backman (S)

Uppsala University, Department of Surgical Sciences, Uppsala, Sweden.

Tobias Åkerström (T)

Uppsala University, Department of Surgical Sciences, Uppsala, Sweden.

Christina Pamporaki (C)

Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Department of Internal Medicine III, Dresden, Germany.

Nicole Bechmann (N)

University Hospital Carl Gustav Carus, Technische Universität Dresden, Institute of Clinical Chemistry and Labaratory Medicine, Dresden, Germany.

Charlotte Lussey-Lepoutre (C)

Pitié-Salpêtrière Hospital, Paris VI University, Cancer Institute, Thyroid and Endocrine Tumors Unit, Department of Nuclear Medicine, Paris, France.

Letizia Canu (L)

University of Florence, Department of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, Florence, Italy.

Rebecca V Steenaard (RV)

Máxima Medical Center, Department of Internal Medicine, Veldhoven/Eindhoven, the Netherlands.

Natacha Driessens (N)

Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Department of Endocrinology, Brussels, Belgium.

Marieke Velema (M)

Slingeland Hospital, Department of Internal Medicine, Division of Endocrinology, Doetinchem, the Netherlands.

Koen M A Dreijerink (KMA)

Amsterdam UMC, location VUmc, Department of Endocrinology and Metabolism, Amsterdam, the Netherlands.

Anton F Engelsman (AF)

Amsterdam UMC, location VUmc, Department of Surgery, Amsterdam, the Netherlands.

Henri J L M Timmers (HJLM)

Radboud University Medical Center, Department of Internal Medicine, Division of Endocrinology, Nijmegen, the Netherlands.

Joanne M de Laat (JM)

Radboud University Medical Center, Department of Internal Medicine, Division of Endocrinology, Nijmegen, the Netherlands.

Classifications MeSH